Pharmacokinetics of omeprazole in cirrhotic patients

M. Rinetti, M. B. Regazzi, P. Villani, M. Tizzoni, R. Sivelli

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.

Original languageEnglish
Pages (from-to)420-422
Number of pages3
JournalArzneimittel-Forschung/Drug Research
Volume41
Issue number4
Publication statusPublished - 1991

Fingerprint

Pharmacokinetics
Omeprazole
Liver
Healthy Volunteers
Liver Diseases
Liver Circulation
Kinetics
Proton-Translocating ATPases
Gastric Acid
Stomach Ulcer
Duodenal Ulcer
Liver Cirrhosis
Population
Adenosine Triphosphatases
Plasmas
Acids

Keywords

  • Antiulcer drugs
  • CAS 73590-58-6
  • Cirrhosis, hepatic
  • Omeprazole, clinical pharmacokinetics

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Pharmacokinetics of omeprazole in cirrhotic patients. / Rinetti, M.; Regazzi, M. B.; Villani, P.; Tizzoni, M.; Sivelli, R.

In: Arzneimittel-Forschung/Drug Research, Vol. 41, No. 4, 1991, p. 420-422.

Research output: Contribution to journalArticle

@article{91bc646b90f44711a9ce80ae48d40f1f,
title = "Pharmacokinetics of omeprazole in cirrhotic patients",
abstract = "Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.",
keywords = "Antiulcer drugs, CAS 73590-58-6, Cirrhosis, hepatic, Omeprazole, clinical pharmacokinetics",
author = "M. Rinetti and Regazzi, {M. B.} and P. Villani and M. Tizzoni and R. Sivelli",
year = "1991",
language = "English",
volume = "41",
pages = "420--422",
journal = "Arzneimittel-Forschung/Drug Research",
issn = "0004-4172",
publisher = "Editio Cantor Verlag GmbH",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of omeprazole in cirrhotic patients

AU - Rinetti, M.

AU - Regazzi, M. B.

AU - Villani, P.

AU - Tizzoni, M.

AU - Sivelli, R.

PY - 1991

Y1 - 1991

N2 - Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.

AB - Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.

KW - Antiulcer drugs

KW - CAS 73590-58-6

KW - Cirrhosis, hepatic

KW - Omeprazole, clinical pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0025853739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025853739&partnerID=8YFLogxK

M3 - Article

C2 - 1859516

AN - SCOPUS:0025853739

VL - 41

SP - 420

EP - 422

JO - Arzneimittel-Forschung/Drug Research

JF - Arzneimittel-Forschung/Drug Research

SN - 0004-4172

IS - 4

ER -